Degenerative Disc Disease Treatment Market Is Expected To Reach Revenue Of USD 66.2 Bn By 2033, At 7.7% CAGR: Dimension Market Research

Advancements and Projections in the Global Degenerative Disc Disease Treatment Market: Insights, Trends, Opportunities, and Recent Developments

New York, Oct. 08, 2024 (GLOBE NEWSWIRE) — Overview – The Global Degenerative Disc Disease Treatment Market is projected to reach USD 34.0 billion by 2024 and rise further towards reaching USD 66.2 billion by 2033 at a CAGR of 7.7%.

The rise in the Geriatric population is among the major drivers behind the rapid expansion in the degenerative disc disease treatment market globally, along with minimally invasive procedures like artificial disc replacement and spinal fusion devices.

Key market players are investing heavily in research and development efforts to create advanced diagnostic tools and treatments, further stimulating market activity with their use among an increasing number of patients.

Click to Request Sample Report and Drive Impactful Decisions: https://dimensionmarketresearch.com/report/degenerative-disc-disease-treatment-market/request-sample/

The US Degenerative Disc Disease Treatment Market with an estimated value of USD 10.8 billion in 2024 is projected to increase at a compound annual growth rate of 7.2% until reaching USD 20.3 billion by 2033.

The United States remains a key contributor to the global degenerative disc disease treatment market due to an aging population and the presence of major companies driving innovation. As people experience increasing symptoms, there is an obvious demand for appropriate medical treatments; currently, this demand is being fulfilled through pharmaceutical products in the form of pain relievers and muscle relaxants. Innovation within spinal fusion devices and artificial discs drives growth within this segment.

Important Insights

• Global Market Size: This market is estimated to be valued at USD 34.0 billion in 2024, with projections to reach USD 66.2 billion by 2033.
• S. Market Size: The U.S. degenerative disc disease treatment market is expected to be valued at USD 10.8 billion in 2024, with growth projected to reach USD 20.3 billion by 2033, reflecting a CAGR of 7.2%.
• Global Growth Rate: The market is forecasted to grow at a CAGR of 7.7% during the projected period.
• Treatment Type Segment: Pharmacological treatments (drugs) are anticipated to dominate this segment, accounting for 61.9% of the market share in 2024.
• Route of Administration Segment: The oral route of administration is expected to lead, commanding 66.7% of the market share in 2024.
• Regional Analysis: North America is projected to hold the largest share of this market, with an estimated 37.9% in 2024.

Latest Trends

• The degenerative disc disease treatment market is gradually moving towards minimally invasive surgical procedures. Such techniques include artificial replacements of discs and modern types of spinal fusions, which normally come along with some benefits faster recovery time, less complication rate, and better maintenance of spinal mobility.
• Orthobiologic therapies represent cutting-edge innovations for treating degenerative disc disease, with gene therapy, cell-based treatments, and tissue engineering taking the forefront in terms of treating its causes as well as alleviating symptoms. These emerging therapies attempt not only to manage symptoms but also alleviate them in terms of alleviating them altogether.
• In treating degenerative disc disease, personalized medicine–therapy tailored specifically to each genetic profile and stage–is becoming increasingly prominent. Genomic advances will drive this focus while proteomics will allow more precise treatment planning.

Degenerative Disc Disease Treatment Market: Competitive Landscape

The competitive scenario for the treatment of degenerative disc disease involves leading companies such as Medtronic, Johnson & Johnson, Zimmer Biomet, and Stryker, which have manufactured sophisticated medical equipment for the treatment of such disorders, including spinal fusion devices and artificial discs.

Other leading pharmaceuticals include Pfizer and Eli Lilly, which offer new pharmacological pain management treatments. Companies like Mesoblast and Vericel Corporation are at the forefront of advanced cell-based and gene therapies in orthobiologic therapies.

The segment also shows strategic mergers and acquisitions, and partnerships in an effort toward innovation for the ever-evolving patient need for degenerative disc disease.

Some of the prominent market players:

• Medtronic plc
• Johnson & Johnson
• Stryker Corporation
• Zimmer Biomet Holdings, Inc.
• NuVasive, Inc.
• Globus Medical, Inc.
• Orthofix International N.V.
• DePuy Synthes (a subsidiary of Johnson & Johnson)
• Spinal Elements, Inc.
• Aesculap Implant Systems, LLC
• Integra LifeSciences Holdings Corporation
• Xtant Medical Holdings, Inc.
• Alphatec Spine, Inc.
• K2M Group Holdings, Inc.
• Other Key Players

Transform your business approach with strategic insights from our report. Get in touch to request our brochure today! : https://dimensionmarketresearch.com/report/degenerative-disc-disease-treatment-market/download-reports-excerpt/

Degenerative Disc Disease Treatment Market Scope

Report Highlights	Details
Market Size (2024)	USD 34.0 Bn
Forecast Value (2033)	USD 66.2 Bn
CAGR (2024-2033)	7.7%
North America Revenue Share (2024)	37.9%
The US Market Size (2024)	USD 10.8 Bn
Historical Data	2018 – 2023
Forecast Data	2024 – 2033
Base Year	2023
Estimate Year	2024
Segments Covered	By Treatment Type, By Route of Administration, By Disease Indication, and By End User
Regional Coverage	North America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA)

Market Analysis

Pharmacological treatments are expected to account for 61.9% of global degenerative disc disease treatment market revenue by 2024, due to their widespread and easy availability for providing symptomatic management of degenerative disc disease treatments.

Fast pain relievers include acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs). Muscle relaxants such as Cyclobenzaprine help manage spasms. Opioids, though potentially addictive, should only be used if severe chronic pain develops, though dependence must always be managed safely for best outcomes.

Typically noninvasive forms of treatment such as pharmaceutical therapies tend to be preferred over such harsh procedures as they provide noninvasive means of managing symptoms more effectively than surgical approaches alone.

Degenerative Disc Disease Treatment Market Segmentation

By Treatment Type

• Pharmacological Treatments (Drugs)
  • Pain Relievers
    • Acetaminophen
    • Non-steroidal anti-inflammatory Drugs (NSAIDs)
      • Ibuprofen
      • Naproxen
  • Muscle Relaxants
    • Cyclobenzaprine
    • Baclofen
• Oral Steroids
  • Prednisone
  • Dexamethasone
• Narcotics (Opioids)
  • Short-Acting Opioids
    • Morphine
    • Oxycodone
    • Hydrocodone
    • Tramadol
• Long-Acting Opioids
  • Methadone
  • Fentanyl
• Others
• Orthobiologic Treatments
  • Biomolecular/Gene Therapy
    • Gene Editing
    • Gene Therapy Vectors
  • Cell-Based Therapy
    • Mesenchymal Stem Cells (MSCs)
    • Induced Pluripotent Stem Cells (iPSCs)
  • Tissue-Based Therapy
    • Allografts
    • Autografts
    • Xenografts
  • Tissue-Engineered Products
    • Synthetic Scaffolds
    • Bioactive Molecules
• Medical Devices
  • Implantable Devices
    • Spinal Fusion Devices
    • Artificial Discs
  • External Devices
    • Back Braces
    • Electrical Nerve Stimulation Devices

 By Route of Administration

• Oral
  • Tablets
  • Capsules
  • Liquids
• Injectable
  • Intravenous (IV)
  • Intramuscular (IM)
  • Subcutaneous (SC)
• Topical
  • Creams
  • Gels
  • Patches

By Disease Indication

• Early Stage
• Mid Stage
• Late Stage

By End User

• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics
• Others

Purchase the Competition Analysis Dashboard Today: https://dimensionmarketresearch.com/checkout/degenerative-disc-disease-treatment-market/

Growth Drivers

• Aging Population and Rising Prevalence: An increasingly aging global population is driving demand for degenerative disc disease treatments, as more people experience conditions like Lumbar Degenerative Disc Disease which increases with each passing year and leads to a greater need for both conservative and surgical therapies to treat Lumbar DDD.
• Technological Advancements in Medical Devices: Developments in medical device technologies such as more durable spinal fusion devices and advanced artificial discs have increased market growth significantly, while robotic-assisted surgery and real-time imaging technologies are providing benefits in complex spinal surgeries by improving results and shortening recovery times.
• Increased Healthcare Spending: Growing healthcare expenditures in developed regions like North America and Europe is driving market expansion. Increased spending allows greater access to advanced treatments, propelling the market ahead.

Restraints

• Expansion into Emerging Markets: Emerging markets across Asia-Pacific and Latin America offer significant expansion potential. Economic expansion, improved healthcare access, and large aging populations such as those found in countries like China and India drive the need for advanced degenerative disc disease treatments that have advanced capabilities.
• Development of Novel Therapies: Novel therapies such as gene therapy and advanced cell-based treatments offer exciting new growth avenues. With potential beyond mere symptom relief to potentially disease-modifying interventions, novel therapies hold great promise as future approaches in healthcare delivery.

Growth Opportunities

• High Treatment Costs: One major obstacle to market expansion is the high costs associated with advanced therapies like spinal fusion surgery and artificial disc replacement procedures, making them inaccessible to many patients, particularly in developing regions. Insurance policies limit patient coverage which makes accessing such costly procedures inaccessible for many.
• Stringent Regulatory Requirements: Strict regulatory requirements can delay new treatments entering the degenerative disc disease treatment market, even while they ensure patient safety – this delays commercialization and ultimately slows market expansion.

Regional Analysis

North America is projected to lead the degenerative disc disease treatment market over its projected period, holding a 37.9% market share by 2024. This high market share can be explained by factors like high rates of disc degeneration among geriatric populations in both North America and Canada and the presence of key market players like advanced medical treatments, solid R&D investments, and well-developed healthcare infrastructure which aid North America’s leadership position.

Further strengthened by favorable reimbursement policies and increasing purchasing power of consumers as they further cement North American as the global degenerative disc disease disease treatment market leader globally.

By Region

North America

• The U.S.
• Canada

Europe

• Germany
• The U.K.
• France
• Italy
• Russia
• Spain
• Benelux
• Nordic
• Rest of Europe

Asia-Pacific

• China
• Japan
• South Korea
• India
• ANZ
• ASEAN
• Rest of Asia-Pacific

Latin America

• Brazil
• Mexico
• Argentina
• Colombia
• Rest of Latin America

Middle East & Africa

• Saudi Arabia
• UAE
• South Africa
• Israel
• Egypt
• Rest of MEA

Discover additional reports tailored to your industry needs

• Lactation Support Supplements Market is expected to reach a value of USD 703.2 million in 2023, and it is further anticipated to reach a market value of USD 1,334.1 million by 2032 at a CAGR of 7.4%.
• Specialty Pharmaceutical Market is projected to reach a value of USD 81.6 billion in 2023 & USD 205.2 billion in 2032 with the anticipated CAGR of 10.8% during the forecast period (2023-2032).
• Optoelectronics Market is projected to reach a market value of USD 50.2 billion by the end of 2023 and is further anticipated to grow the market value of USD 86.5 billion by 2032, at a CAGR of 6.2%.
• Insulin Pump Market is expected to reach a market value of USD 6.5 billion in 2023 and is further anticipated to reach a value of USD 28.0 billion at a CAGR of 17.6% for the forecast period (2023-2032).
• Hand Sanitizers Market is expected to hold a market value of USD 7.3 billion in 2023 and is projected to show subsequent growth with a market value of USD 13.6 billion in 2032 at a CAGR of 7.2%.
• exoskeleton Market is expected to reach a value of USD 417.7 million in 2023, and it is further anticipated to reach a market value of USD 1,903.3 million by 2032 at a CAGR of 18.4%.
• Dental Implant Market is expected to reach a value of USD 5.3 billion in 2023, and it is further anticipated to reach a market value of USD 13.3 billion by 2032 at a CAGR of 10.7%.
• Breast Pump Market is expected to be valued of USD 3.2 billion in 2023 & USD 7.0 billion in 2032, and projections indicate a CAGR of 9.2% for the forecasted period of 2023 to 2032.
• Health and Wellness Market is expected to reach a value of USD 3,812.3 billion in 2023, and it is further anticipated to reach a market value of USD 5,499.9 billion by 2032 at a CAGR of 4.2%.

Recent Developments in the Global Degenerative Disc Disease Treatment Market

• August 2024: Medtronic launched their next-generation spinal fusion device to enhance surgical outcomes and decrease recovery times for those living with degenerative disc disease.
• July 2024: Pfizer gained FDA approval for an oral medication designed to decrease inflammation among mid-stage degenerative disc disease patients.
• June 2024: Zimmer Biomet entered a partnership agreement with one of the world’s premier research institutions to develop an early-stage degenerative disc disease gene therapy treatment protocol.
• May 2024: Stryker successfully acquired an orthobiologic company to expand their product offering within the degenerative disc disease treatment market.
• April 2024: Johnson & Johnson introduced new artificial discs offering increased durability and better patient outcomes.
• March 2024: Vericel Corporation announced promising results of their clinical trial testing a cell-based therapy intended to treat late-stage degenerative disc disease.
• February 2024: Mesoblast gained regulatory approval for their mesenchymal stem cell therapy designed specifically to treat mid-stage degenerative disc disease patients.
• January 2024: Eli Lilly unveiled their pain management medication designed for individuals suffering chronic degenerative disc pain due to degeneration.

Click to Request Sample Report and Drive Impactful Decisions: https://dimensionmarketresearch.com/report/degenerative-disc-disease-treatment-market/request-sample/

About Dimension Market Research (DMR):

Dimension Market Research (DMR) is a market research and consulting firm based in India & US, with its headquarters located in the USA (New York). The company believes in providing the best and most valuable data to its customers using the best resources analysts work, to create unmatchable insights into the industries, and markets while offering in-depth results of over 30 industries, and all major regions across the world.

We also believe that our clients don’t always want what they see, so we provide customized reports as well, as per their specific requirements to create the best possible outcomes for them and enhance their business through our data and insights in every possible way.